Search results
Meet the Gilead Senior Management team and the board of directors and learn more about their roles within Gilead Sciences, Inc.
At Gilead, we’re committed to creating possible. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases and improving care for people across Canada and around the world.
Gilead is committed to advancing care for patients around the world by bringing forward medicines in areas of unmet medical need. We do this through internal research and development, as well as through collaborations with academic and industry partners. Together, we can help end the HIV epidemic for everyone, everywhere.
Find the latest Gilead Sciences, Inc. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Jul 14, 2023 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury ® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people ...
Get the latest Gilead Sciences, Inc. (GILD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Dec 22, 2022 · Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
